BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36382415)

  • 1. Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors.
    van de Beek I; Glykofridis IE; Wagner A; den Toom DT; Bongers EMHF; van Leenders GJLH; Johannesma PC; Meijers-Heijboer HEJ; Wolthuis RMF; van Steensel MAM; Dubbink HJ; Houweling AC
    Mol Genet Genomic Med; 2023 Feb; 11(2):e2098. PubMed ID: 36382415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP; Mishra T; Reintjes N; Fabretti F; Gharbi H; Adam AC; Göbel H; Franke M; Schermer B; Haneder S; Benzing T; Beck BB; Müller RU
    BMC Med Genet; 2017 May; 18(1):53. PubMed ID: 28499369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-Wide Uniparental Disomy and Copy Number Variations in Renal Cell Carcinomas Associated with Birt-Hogg-Dubé Syndrome.
    Iribe Y; Yao M; Tanaka R; Kuroda N; Nagashima Y; Nakatani Y; Furuya M
    Am J Pathol; 2016 Feb; 186(2):337-46. PubMed ID: 26776076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
    Enomoto Y; Namba Y; Hoshika Y; Komemushi Y; Mitani K; Kume H; Kobayashi E; Miyama Y; Homma Y; Ushiku T; Seyama K
    Eur J Med Genet; 2020 Apr; 63(4):103820. PubMed ID: 31778855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.
    Gatalica Z; Lilleberg SL; Vranic S; Eyzaguirre E; Orihuela E; Velagaleti G
    Hum Pathol; 2009 Dec; 40(12):1813-9. PubMed ID: 19733897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
    Schneider M; Dinkelborg K; Xiao X; Chan-Smutko G; Hruska K; Huang D; Sagar P; Harisinghani M; Iliopoulos O
    Fam Cancer; 2018 Jan; 17(1):135-139. PubMed ID: 28623476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
    Klomp JA; Petillo D; Niemi NM; Dykema KJ; Chen J; Yang XJ; Sääf A; Zickert P; Aly M; Bergerheim U; Nordenskjöld M; Gad S; Giraud S; Denoux Y; Yonneau L; Méjean A; Vasiliu V; Richard S; MacKeigan JP; Teh BT; Furge KA
    BMC Med Genomics; 2010 Dec; 3():59. PubMed ID: 21162720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.
    Dong L; Gao M; Hao WJ; Zheng XQ; Li YG; Li XL; Yu Y
    Medicine (Baltimore); 2016 May; 95(22):e3695. PubMed ID: 27258496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC; Gijezen LM; Jonker MA; van Doorn MB; Oldenburg RA; van Spaendonck-Zwarts KY; Leter EM; van Os TA; van Grieken NC; Jaspars EH; de Jong MM; Bongers EM; Johannesma PC; Postmus PE; van Moorselaar RJ; van Waesberghe JH; Starink TM; van Steensel MA; Gille JJ; Menko FH
    Br J Cancer; 2011 Dec; 105(12):1912-9. PubMed ID: 22146830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed diagnosis of Birt-Hogg-Dubé syndrome due to marked intrafamilial clinical variability: a case report.
    Sattler EC; Steinlein OK
    BMC Med Genet; 2018 Mar; 19(1):45. PubMed ID: 29548312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
    Nahorski MS; Lim DH; Martin L; Gille JJ; McKay K; Rehal PK; Ploeger HM; van Steensel M; Tomlinson IP; Latif F; Menko FH; Maher ER
    J Med Genet; 2010 Jun; 47(6):385-90. PubMed ID: 20522427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.